Companies: 10,795·Total market cap: $144.5T
Aspire Biopharma Holdings, Inc.

Aspire Biopharma Holdings, Inc.

ASBPNASDAQHealthcare● Active
$6.65
+$1.31(+24.53%)
Market Cap$767224
P/E Ratio
52W High$35
52W Low$0.11
SEC Filings

Aspire Biopharma Holdings, Inc. (ASBP) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001847345 · ASBP · NASDAQ · as of Jun 9, 2026

Filing snapshot

212
Total Filings
10-Q
Latest Form
2026-05-15
Most Recent
2025
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001847345 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-04-08
Fiscal Year End
Apr 8, 2026
Accession No.
0001493152-26-015737
Primary Document
form10-ka.htm
Source: data.sec.gov · CIK 0001847345 · Accession 0001493152-26-015737

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-15
8-KCurrent Report
8-K
2026-05-14Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
10-QQuarterly Report
10-Q
2026-05-15
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-15
View
8-KCurrent Report
8-K
2026-05-14
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-13
View
DEFR14ADEFR14A
DEFR14A
2026-05-12
View
DEF 14AProxy Statement
DEF 14A
2026-05-08
View
PRE 14APRE 14A
PRE 14A
2026-04-27
View
8-KCurrent Report
8-K
2026-04-20
View
8-K/ACurrent Report (Amended)
8-K/A
2026-04-17
View
8-KCurrent Report
8-K
2026-04-16
View
8-KCurrent Report
8-K
2026-04-16
View
8-KCurrent Report
8-K
2026-04-16
View
8-KCurrent Report
8-K
2026-04-15
View
EFFECTEFFECT
EFFECT
2026-04-14
View
CORRESPCORRESP
CORRESP
2026-04-13
View
Showing 1–15 of 208 filingsForm 4 / 144 hidden· 212 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001847345  |  Exchange: NASDAQ · Healthcare

Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) has submitted 212 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2025. As a Healthcare sector company with CIK 0001847345, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Aspire Biopharma Holdings, Inc.'s most comprehensive regulatory disclosure. The most recent Aspire Biopharma Holdings, Inc. 10-K was filed on 2026-04-08 for fiscal year ending 2026. Historical ASBP 10-K annual reports are available from 2021 through 2026.

Investors researching Aspire Biopharma Holdings, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

ASBP SEC Filings · 8 questions

Aspire Biopharma Holdings, Inc. (ASBP) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 212 filings and access original documents at no cost. Aspire Biopharma Holdings, Inc.'s CIK is 0001847345.

ASBP SEC filingsAspire Biopharma Holdings, Inc. SEC documentsfind ASBP 10-K